A new method to deliver drugs directly to eye cells for glaucoma treatment
A Nanocarrier Platform for Targeting Schlemm's Canal Cells
This study is looking at new tiny drug carriers that can directly target specific cells in the eye to help manage eye pressure for people with glaucoma, aiming to make treatments more effective and comfortable by reducing side effects and the need for frequent injections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10886675 on NIH RePORTER |
What this research studies
This research focuses on developing nanoscale drug carriers that can specifically target Schlemm's canal cells in the eye, which are important for managing intraocular pressure in glaucoma patients. By using these nanocarriers, the goal is to reduce side effects and improve the effectiveness of glaucoma treatments. The approach aims to create a sustained delivery system that minimizes the need for frequent injections, making it more comfortable for patients. The research also explores gene therapy as a potential long-term solution for glaucoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glaucoma who are currently experiencing side effects from existing treatments.
Not a fit: Patients who do not have glaucoma or those who are not responsive to current glaucoma therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective glaucoma treatments with fewer side effects and less frequent need for injections.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems for other conditions, suggesting potential success for this novel approach in glaucoma treatment.
Where this research is happening
Chicago, UNITED STATES
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Johnson, Mark — Northwestern University
- Study coordinator: Johnson, Mark
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.